Press Releases

Press Releases In the News

Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations

Agreement supports late-stage clinical study for ACG-701 beginning in 2022 Advances Aceragen’s development effort to treat life-threatening rare and orphan diseases RALEIGH-DURHAM, NC – January 06, 2022 – Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today announced that its wholly-owned subsidiary, Arrevus, Inc., has received

Arrevus: Patient-driven breakthroughs

Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis

Agreement supports development, manufacturing, and Phase 2 clinical development Program provides significant value to Aceragen’s overall development of ACG-701 for the treatment of life-threatening orphan infectious diseases RALEIGH-DURHAM, NC – January 05, 2022 – Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, today announced it has